ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

ClinicalTrials.gov ID: NCT03845166

Public ClinicalTrials.gov record NCT03845166. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Study identification

NCT ID
NCT03845166
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Exelixis
Industry
Enrollment
325 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 19, 2019
Primary completion
Aug 30, 2026
Completion
May 30, 2027
Last update posted
Nov 18, 2024

2019 – 2027

United States locations

U.S. sites
40
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
Exelixis Clinical Site #6 Duarte California 91010
Exelixis Clinical Site #49 La Jolla California 92093
Exelixis Clinical Site #7 Los Angeles California 90025
Exelixis Clinical Site #84 Los Angeles California 90095
Exelixis Clinical Site #66 San Francisco California 94158
Exelixis Clinical Site #71 Stanford California 94305
Exelixis Clinical Site #15 Lake Mary Florida 32746
Exelixis Clinical Site #24 Miami Florida 33136
Exelixis Clinical Site #11 Atlanta Georgia 30322
Exelixis Clinical Site #80 Atlanta Georgia 30342
Exelixis Clinical Site #41 Iowa City Iowa 52242
Exelixis Clinical Site #36 Westwood Kansas 66205
Exelixis Clinical Site #62 Scarborough Maine 04074
Exelixis Clinical Site #44 Baltimore Maryland 21201
Exelixis Clinical Site #4 Boston Massachusetts 02215
Exelixis Clinical Site #45 Ann Arbor Michigan 48109
Exelixis Clinical Site #2 Grand Rapids Michigan 49546
Exelixis Clinical Site #25 Saint Paul Minnesota 55101
Exelixis Clinical Site #13 Omaha Nebraska 68130
Exelixis Clinical Site #9 East Brunswick New Jersey 08816
Exelixis Clinical Site #83 New Brunswick New Jersey 08903
Exelixis Clinical Site #86 New York New York 10021
Exelixis Clinical Site #35 New York New York 10029
Exelixis Clinical #78 New York New York 10065
Exelixis Clinical Site #85 The Bronx New York 10461
Exelixis Clinical #74 Cincinnati Ohio 45219
Exelixis Clinical Site #60 Cleveland Ohio 44106
Exelixis Clinical Site #59 Hershey Pennsylvania 17033
Exelixis Clinical Site #58 Philadelphia Pennsylvania 19107
Exelixis Clinical Site #12 Pittsburgh Pennsylvania 15232
Exelixis Clinical Site #61 Charleston South Carolina 29425
Exelixis Clinical Site #50 Myrtle Beach South Carolina 29572
Exelixis Clinical Site #33 Germantown Tennessee 38138
Exelixis Clinical Site #87 Nashville Tennessee 37203
Exelixis Clinical Site #3 Houston Texas 77030
Exelixis Clinical Site #1 San Antonio Texas 78229
Exelixis Clinical Site #5 Salt Lake City Utah 84112
Exelixis Clinical Site #8 Charlottesville Virginia 22903
Exelixis Clinical Site #43 Richmond Virginia 23219
Exelixis Clinical Site #26 Spokane Washington 99208

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03845166, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2024 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03845166 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →